408 Preliminary biomarker and clinical ata of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer

• Cara Haymaker,
• Aung Naing,
• Shubham Pant,
• Minal Barve,
• Dae Won Kim,
• Richard Kim,
• Melissa Johnson,
• Marya Chaney,
• Robert Wolff,
• Jean Fan,
• Byung Ha Lee,
• NgocDiep Le,
• Sara Ferrando-Martinez,
• Hirva Mamdani

Affiliations

Cara Haymaker

1The University of Texas MD Anderson Cancer Center, Bellaire, TX, USA

Aung Naing

Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA

Shubham Pant

Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA

Minal Barve

Aff462 grid.416487.80000000404554449Mary Crowley Cancer Research Centers, Texas Oncology, P.A Dallas TX USA

Dae Won Kim

Aff272 grid.468198.a0000000098915233H. Lee Moffitt Cancer Center Tampa FL USA

Richard Kim

Anesthesiology, Perioperative, and Pain Medicine, Stanford University School of Medicine, Stanford, California, USA

Melissa Johnson

3Sarah Cannon Research Institute, Nashville, TN, USA

Marya Chaney

7Merck and Co, Inc., Kenilworth, NJ, USA

Robert Wolff

medical doctor

Jean Fan

2NeoImmuneTech, Inc., Rockville, MD, USA

Byung Ha Lee

2NeoImmuneTech, Inc., Rockville, MD, USA

NgocDiep Le

2NeoImmuneTech, Inc., Rockville, MD, USA

Sara Ferrando-Martinez

6NeoImmuneTech, Inc., Rockville, MD, USA

Hirva Mamdani

8Karmanos Cancer Institute, Detroit, USA